Randomised controlled trialindependent cross-checkabstract checked★ key study I-CAN-125 in-depth review
Ketogenic diet added to chemotherapy for pancreatic cancer: early trial
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.
Overview
Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343
In 32 patients, adding a supervised ketogenic diet to chemotherapy showed a trend toward longer survival that was not statistically confirmed.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Test a ketogenic diet added to chemotherapy.
- How was the study done?
Randomised phase II trial.
- How many people, animals or samples were studied?
32 patients.
- What was actually found?
Trends toward longer PFS/OS.
- How large was the observed effect?
PFS HR 0.53 (0.21-1.37).
- What do the results mean in everyday life?
Diet research in cancer is about adding to treatment, not replacing it.
- What are the study's limitations?
Small; uncertain; COI.
- What does it say about Elawady's specific claim?
Does not support diet instead of treatment.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Any proven survival benefit.
Scientific in-depth review
1. Full reference
- Authors
- Jameson GS et al.
- Journal
- Cancer
- Year
- 2026
- Identifier
- PMID 41817106 DOI 10.1002/cncr.70343
- Verification
- verified – PubMed efetch 2026-10-26 + Crossref
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Funding: Ludwig Institute, Sabga Foundation and others; one author employed by Virta Health (ketogenic-diet company); several authors with industry ties (PubMed record)
2. Research question
Does a medically supervised ketogenic diet added to gemcitabine, nab-paclitaxel and cisplatin improve outcomes in metastatic pancreatic cancer?
3. Study design and population
- Study design
- Randomised controlled trial – Randomised phase II screening trial (1:1), chemotherapy with vs without a medically supervised ketogenic diet
- Population
Treatment-naive metastatic pancreatic ductal adenocarcinoma
- Country
USA
- Period
Published 2026
- Sample size
32 evaluable patients
- Inclusion and exclusion criteria
Untreated metastatic PDAC
4. Methods and endpoints
- Exposure / intervention
Medically supervised ketogenic diet (remote team, daily ketone monitoring) plus chemotherapy
- Comparator
Usual diet plus the same chemotherapy
- Endpoints
Progression-free survival (primary, one-sided alpha 0.20); overall survival, safety, QoL; microbiome (exploratory)
- Statistical methods
Hazard ratios; one-sided tests
5. Actual results
- Results
Median PFS 8.5 vs 6.2 months, HR 0.53 (95% CI 0.21-1.37), one-sided p=.096; median OS 13.7 vs 10.2 months, HR 0.58 (0.25-1.37), one-sided p=.107. 15 of 16 diet patients reached ketosis (median 39.4% of days). Diet-related adverse events grade 1-2; no difference in grade >=3 chemotherapy toxicity; no QoL decline.
- Absolute risks
Median PFS/OS differences 2.3 and 3.5 months (not statistically established)
- Authors' conclusion
The diet is feasible and shows trends toward improved PFS and OS when combined with chemotherapy; larger studies required.
6. Strengths
- Randomised
- Diet added to standard chemotherapy
- Supervised
7. Weaknesses
- Very small (n=32)
- One-sided alpha 0.20 screening design
- CIs include no effect
- Commercial COI
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Open-label; small; screening design; COI.
9. Assessment of the statistical interpretation
Wide CIs (0.21-1.37) compatible with large benefit and with harm; a phase II screening signal only.
10. Relevance to the specific claim
Strongest available evidence that a diet might add benefit to cancer treatment - but only together with chemotherapy, under medical supervision, unconfirmed, and with a different diet than Tayebat.
11. Independent contrary findings
Shows the opposite of the claim's practical advice: the diet was tested as an addition to chemotherapy, not instead of it.
12. Transferability to Germany and Europe
Moderate.
13. Overall methodological judgement
Hypothesis-generating; supports research on diet as an adjunct, not diet as treatment.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | indirect |
| Reproducibility | not replicated |
| Consistency with the overall evidence | unknown |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Phase III confirmation.
15. Linked fact checks
- Cancer will respond to the Tayebat system; a patient with a malignant tumour should start the system now (diet as cancer treatment). – Studies with mixed or unclear results
- The idea that 'sugar feeds cancer' should be dropped: sugar feeds every cell (and microbe), so cancer patients need not fear sugar. – Studies with mixed or unclear results